Lansoprazol Pharma Combix

Lansoprazole, the active ingredient in Lansoprazol Pharma Combix, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and erosive esophagitis in adult patients, and it is indicated for adult patients requiring long‑term acid control.

GNH USA supplies Lansoprazol Pharma Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU manufacturing standards and is intended for distribution through qualified healthcare channels.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, promotes healing of the esophageal mucosa. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid production. - Erosive esophagitis: alleviates mucosal damage and supports regeneration of the esophageal lining. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.

Lansoprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild, transient headache reported in some patients. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): potentially life‑threatening hypersensitivity. - Clostridioides difficile‑associated diarrhea: severe colitis linked to bacterial overgrowth. - Low magnesium (hypomagnesemia): can cause muscle weakness, arrhythmias, or seizures.

Before prescribing Lansoprazole, several precautionary measures should be considered. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor magnesium levels: prolonged use can lead to hypomagnesemia. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Caution in liver disease: use with care in patients with hepatic impairment. - Review concomitant medications: potential interactions may require monitoring. - Store below 25°C: keep in the original pack, protect from moisture.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: increased risk of elevated lansoprazole levels and cardiac arrhythmias. - Ketoconazole: reduced absorption of ketoconazole, decreasing its efficacy. - Atazanavir: markedly decreased atazanavir exposure, compromising HIV therapy. - HIV protease inhibitors (e.g., ritonavir): significant reduction in antiviral drug levels.

Moderate Interactions (Monitor Closely): - Amiodarone: may increase amiodarone plasma concentration, requiring ECG monitoring. - Digoxin: higher digoxin levels possible; monitor therapeutic range. - Warfarin: enhanced anticoagulant effect; monitor INR closely.